CLINICAL_TRIALS ClinicalTrials.gov record update

Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" General Investigation (Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03885089
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:40.745335+00:00
Published At: 2025-06-19T00:00:00+00:00
Record Updated At: 2025-06-19
Results Posted At: 2025-06-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Psoriasis Vulgaris", "Psoriasis Arthropathica", "Pustular Psoriasis", "Erythrodermic Psoriasis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-06-19"
protocolSection.identificationModule.nctId: "NCT03885089"
protocolSection.identificationModule.officialTitle: "Infliximab BS for Intravenous Drip Infusion 100 mg \"Pfizer\" General Investigation (Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-06-19"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.